EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Gut microbiota and polyendocrine metabolic ovarian syndrome: an integrated gut–metabolism–endocrine–ovary axis

Shengyue Jin, Menglei Zhu, Yiyang Lu, Jia Zhao, Jiayi Zhu, Xiaohong Fang

Experimental Biology and Medicine · 10.07.2026 · 251

DOI: 10.3389/ebm.2026.11058 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Experimental Biology and Medicine, online erschienen am 10.07.2026. Verfasst von Shengyue Jin und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of TCM Gynecology, Hangzhou TCM Hospital of Zhejiang Chinese Medical University (Hangzhou Hospital of Traditional Chinese Medicine), Hangz…. Hauptthemen laut MEDLINE: Polycystic Ovary Syndrome, Gastrointestinal Microbiome, Ovary. Die Arbeit nennt 120 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Polyendocrine metabolic ovarian syndrome (PMOS), previously known as polycystic ovary syndrome (PCOS), is a common endocrine and metabolic disorder in reproductive-age women, characterized by marked clinical and biological heterogeneity. Accumulating evidence suggests that gut microbiota dysbiosis is associated with metabolic disturbances, hormonal imbalance, and ovarian dysfunction in PMOS. However, the pathways linking gut microbiota alterations to PMOS pathogenesis remain incompletely understood, and most evidence remains associative. This review aims to summarize current evidence regarding interactions between gut microbiota and PMOS, clarify the roles of key microbiota-derived metabolites, and evaluate the potential and limitations of gut microbiota–targeted interventions. A major novelty is the proposal of an integrated gut–metabolism–endocrine–ovary axis incorporating phenotypic heterogeneity, methodological variability, and evidence grading across clinical and preclinical studies. A narrative review with a systematic literature search was conducted. PubMed, Web of Science, Embase, and CNKI were searched from inception to March 2026 using terms related to PMOS, gut microbiota, microbial metabolites, and microbiota-targeted interventions. Eligible studies included human observational or interventional studies, animal experiments exploring microbiota–PMOS mechanisms, and peer-reviewed full-text articles in English or Chinese. Case reports, letters, conference abstracts, non-English publications, and irrelevant studies were excluded. Duplicate records were removed. Two authors independently screened records and resolved disagreements by consensus. No meta-analysis was performed, and clinical registration was not applicable. Gut microbiota dysbiosis may contribute to PMOS through chronic low-grade inflammation, insulin resistance, and hyperandrogenism. Microbiota-derived metabolites link intestinal dysbiosis with metabolic and endocrine dysfunction. Bile acids and short-chain fatty acids exert regulatory effects, whereas amino acid disorders and LPS-mediated endotoxemia amplify metabolic and inflammatory abnormalities. Considerable heterogeneity exists across studies regarding obesity, insulin resistance, hyperandrogenism, diet, ethnicity, region, and methodology. Microbiota-targeted interventions show potential, although evidence quality varies and most findings remain associative. Gut microbiota dysbiosis is a critical regulatory node within the integrated gut–metabolism–endocrine–ovary axis in PMOS. This review highlights phenotypic stratification, evidence hierarchy, and clinical translation potential. Although microbiota-targeted strategies may serve as adjunctive therapies, their causal roles and long-term efficacy require confirmation in well-designed longitudinal and randomized controlled trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Polycystic Ovary SyndromeGastrointestinal MicrobiomeOvaryHumansFemaleAnimalsDysbiosis

Stichwörter der Autor:innen

bile acidsgut microbiotahyperandrogenisminsulin resistancemicrobiota-derived metabolitespolycystic ovary syndromepolyendocrine metabolic ovarian syndromeshort-chain fatty acids

Autor:innen und Institutionen

  • Department of TCM Gynecology, Hangzhou TCM Hospital of Zhejiang Chinese Medical University (Hangzhou Hospital of Traditional Chinese Medicine), Hangzhou, Zhejiang, China.

Zitieren

APA

Jin, S., Zhu, M., Lu, Y., Zhao, J., Zhu, J., & Fang, X. (2026). Gut microbiota and polyendocrine metabolic ovarian syndrome: an integrated gut–metabolism–endocrine–ovary axis. Experimental Biology and Medicine, 251. https://doi.org/10.3389/ebm.2026.11058

Vancouver

Jin S, Zhu M, Lu Y, Zhao J, Zhu J, Fang X. Gut microbiota and polyendocrine metabolic ovarian syndrome: an integrated gut–metabolism–endocrine–ovary axis. Experimental Biology and Medicine. 2026;251. doi:10.3389/ebm.2026.11058

BibTeX
@article{Jin2026,
  author = {Jin, Shengyue and Zhu, Menglei and Lu, Yiyang and Zhao, Jia and Zhu, Jiayi and Fang, Xiaohong},
  title = {Gut microbiota and polyendocrine metabolic ovarian syndrome: an integrated gut–metabolism–endocrine–ovary axis},
  journal = {Experimental Biology and Medicine},
  year = {2026},
  volume = {251},
  doi = {10.3389/ebm.2026.11058}
}
Kostenlos starten →